Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $23.34 USD
Change Today +0.21 / 0.91%
Volume 904.8K
HALO On Other Exchanges
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

halozyme therapeutics inc (HALO) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/23/15 - $25.25
52 Week Low
12/16/14 - $7.51
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

halozyme therapeutics inc (HALO) Related Businessweek News

No Related Businessweek News Found

halozyme therapeutics inc (HALO) Details

Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter abnormal tissue structures for clinical benefit. The company’s products are based on the Enhanze technology, a patented human recombinant hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs; in subcutaneous urography; and to enhance resorption of radiopaque agents. The company is also developing PEGPH20, a new molecular entity that is in Phase II clinical trials for the treatment of metastatic pancreatic cancer, as well as in Phase I clinical trial for the treatment of non-small cell lung cancer; and Hylenex recombinant for use as pre-treatment in patients with type 1 diabetes using pumps and recombinant human cathepsin L (HTI-501) for the treatment of cellulite. It has collaborative partnerships with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxter Healthcare Corporation; Pfizer Inc.; Janssen Biotech, Inc.; and Eisai Co., Ltd. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.

153 Employees
Last Reported Date: 03/2/15
Founded in 1998

halozyme therapeutics inc (HALO) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $1.6M
Compensation as of Fiscal Year 2014.

halozyme therapeutics inc (HALO) Key Developments

Eisai Co., Ltd. and Halozyme Therapeutics, Inc. Sign Collaboration Agreement to Investigate Halaven® (Eribulin) and PEGPH20 in Metastatic Breast Cancer

Eisai Co., Ltd. and Halozyme Therapeutics, Inc. signed a clinical collaboration agreement that will evaluate Halaven® (eribulin) in combination with Halozyme's investigational PEGPH20 (PEGylated recombinant human hyaluronidase) in first line HER2-negative metastatic breast cancer. Under the agreement, the companies will jointly conduct and share the costs of a Phase 1b/II clinical study seeking to determine whether the combination therapy of eribulin and PEGPH20 can improve overall response rate (the proportion of women that have a predefined reduction in tumour burden), in advanced breast cancer patients with high levels of hyaluronan. PEGPH20 is an investigational drug administered intravenously that targets the degradation of hyaluronan, a glycosaminoglycan - or chain of natural sugars throughout the body - that can accumulate around cancer cells to inhibit other therapies. By degrading hyaluronan, PEGPH20 increases blood flow to the tumour which may allow cancer therapies to be more efficiently delivered to their target. The collaborative study will seek to determine whether the combination therapy of eribulin and PEGPH20 can improve overall response rate in patients with high levels of hyaluronan. In hyaluronan-rich triple-negative breast preclinical animal models, the addition of PEGPH20 to eribulin significantly increased tumour growth inhibition and overall tumour regressions, when compared to eribulin alone. Eribulin is the first in the halichondrin class of microtubule dynamics inhibitors with a novel mechanism of action. Structurally eribulin is a modified and synthetically produced analog of halichondrin B, a natural product isolated from the marine sponge Halichondria okadai. Eribulin is believed to work by inhibition of the growth phase of microtubule dynamics which prevents cell division. Eribulin is currently approved in more than 60 countries around the world, which include all of the European Union, Canada, United States, Russia, Switzerland, South Korea, Japan and Singapore. Eribulin remains the only single agent chemotherapy to significantly improve overall survival in women with advanced breast cancer after anthracycline and taxane treatment. Advanced or metastatic breast cancer is a very difficult condition to treat and only 25.9% of women will survive beyond five years.

Halozyme Therapeutics, Inc. Announces Executive Changes Effective June 15, 2015

Halozyme Therapeutics, Inc. announced its chief financial officer David Ramsay will retire this summer, and named biotech veteran Laurie Stelzer as his successor. Stelzer will assume CFO duties on June 15, 2015 and will work with Ramsay through a transition period. Most recently at Shire, Stelzer served as senior vice president of Finance for R&D, Technical Operations and Business Development, and was previously Division CFO for Regenerative Medicine. Before Shire, she spent 15 years at Amgen, in senior leadership roles in finance and business development with responsibilities including the U.S., Canada and International Markets, ultimately serving as the company's acting treasurer. In this role, she led a leveraged recapitalization that included $10 billion in bond offerings and the corresponding expanded share buyback program, which contributed to an increase in shareholder value.

Halozyme Enters into Global Collaboration and Licensing Agreement with AbbVie

Halozyme Therapeutics, Inc. announced a global collaboration and license agreement with AbbVie to develop and commercialize products combining proprietary AbbVie compounds with Halozyme's ENHANZE™ platform. Under the terms of the agreement, Halozyme will receive an initial $23 million payment, followed by milestone payments totaling approximately $130 million for each of up to nine collaboration targets. These payments are subject to AbbVie's achievement of specified development, regulatory and sales-based milestones. In addition, AbbVie will pay Halozyme tiered royalties if products under the collaboration are commercialized.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HALO:US $23.34 USD +0.21

HALO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amphastar Pharmaceuticals Inc $16.26 USD +0.51
Valeant Pharmaceuticals International Inc C$335.61 CAD +4.75
View Industry Companies

Industry Analysis


Industry Average

Valuation HALO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 35.6x
Price/Book 77.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 34.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HALOZYME THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at